Bradley gets sector perform rating from RBC

Bradley Pharmaceuticals Inc. was rated at sector perform, speculative risk, with an $11 price target, by RBC Capital Markets analyst Ken Trbovich as the company restated first-quarter earnings per share up $0.03 to $0.01. Bradley continues to struggle due to increased product returns from generic competition across the majority of its brands. The approval of Ranbaxy's 50 mg, 75 mg and 100 mg doxycycline tablets in early June causes additional concern. Shares of the Fairfield, N.J.-based pharmaceutical company were up 50 cents, or 5.20%, at $10.11 on volume of 310,000 shares versus the three-month running average of 270,303 shares. (NYSE: BDY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.